The largest database of trusted experimental protocols

15 protocols using tapi 2

1

Thawing and Preparing Cryopreserved Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cryopreserved samples were thawed in a 37°C water bath and vial contents transferred to a 15 mL Falcon tube. Pre-warmed defrost media (RPMI (Glutamax with HEPES) (Life Technologies (Thermo Fisher)), 5% human AB serum (Sigma), 20 nM TAPI-2 (Sigma), 50 U/mL Benzonase (Sigma) was added dropwise to 10 mL. Cells were rested in 4 mL resting media (RPMI with 10% human AB serum, 20 nM TAPI-2) for 1 hour at 37°C. 2 x 106 (link) cells were used for subsequent flow cytometry staining.
+ Open protocol
+ Expand
2

Thawing and Preparing Cryopreserved Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cryopreserved samples were thawed in a 37°C water bath and vial contents transferred to a 15 mL Falcon tube. Pre-warmed defrost media (RPMI (Glutamax with HEPES) (Life Technologies (Thermo Fisher)), 5% human AB serum (Sigma), 20 nM TAPI-2 (Sigma), 50 U/mL Benzonase (Sigma) was added dropwise to 10 mL. Cells were rested in 4 mL resting media (RPMI with 10% human AB serum, 20 nM TAPI-2) for 1 hour at 37°C. 2 x 106 (link) cells were used for subsequent flow cytometry staining.
+ Open protocol
+ Expand
3

Glioblastoma Cell Culture Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
PIGPCs were isolated as previously described [39 (link)] and grown in DMEM (Life Technologies) with 10% fetal bovine serum (FBS) and 1% PenStrep solution (Corning). U3046MG, U3035MG, U3082MG, U3084MG, and U3065MG cells were obtained from the Human Glioblastoma Cell Culture Resource (HGCC) and cultured as described previously [23 (link)] in Neurobasal (GIBCO) and DMEM/F12 with Glutamax media (Life Technologies), 1:1 mix, with 1% PenStrep, N2 and B27 (Life Technologies), 10 ng/mL epidermal growth factor (EGF), and 10 ng/mL fibroblast growth factor (FGF) (Peprotech). Cells were dissociated by Accutase (ThermoFisher) treatment, and grown as a monolayer on plastic dishes coated with polyornithine (Sigma) and laminin (Biolamina). U251MG and T98G cells were obtained from ATCC and grown in DMEM with 10% FBS and 1% PenStrep solution. Cells were used within ten passages. Mycoplasma contamination was tested every 3 months.
Hypoxia (1%O2) was generated in a Whitley H35 Hypoxystation (Don Whitley Scientific, Bingley, UK).
Reagents: TAPI-2 (Sigma), MI1 (Tocris Bioscience), LY294002 (Sigma), added 24 h pre-hypoxia exposure.
+ Open protocol
+ Expand
4

Intracerebroventricular Infusion of TAPI-2 Inhibitor

Check if the same lab product or an alternative is used in the 5 most similar protocols
The p75NTR metalloprotease inhibitor TAPI-2 (Sigma–Aldrich, St. Louis, MO, USA) was intracerebroventricular injected by the osmotic pump infusion 4 days before 5-bromo-2′-deoxyuridine (BrdU) injection (Figure 1). The mouse was placed in the stereotaxic instrument (Stoelting, Wood Dale, IL, USA), and a 7-day Alzet osmotic minipump (mean flow rate, 0.25 μl/h) containing TAPI-2 (50 mmol/l; Katakowski et al., 2007 (link)) or sterile saline was placed subcutaneously in the back. A brain infusion cannula connected to the pump that was positioned at right lateral ventricle (0.3 mm posterior, 1.0 mm lateral, and 2.3 mm ventral to Bregma).
+ Open protocol
+ Expand
5

Bone Marrow-Derived Macrophage Infection Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Bone marrow-derived macrophages (BMDMs) from C57BL/6J (Jackson), Tnfrsf1a−/− (23 (link)) (Jackson), Trif−/− (24 (link)) and Trif−/−Tnfr1−/− mice (25 (link)) were cultured and infected as previously described (19 (link)). Y. pseudotuberculosis strain IP2666 and isogenic yopJ mutant bacteria were grown overnight with aeration in 2×YT broth at 26 °C. Yp were diluted into inducing media (2×YT containing 20mM sodium oxalate and 20mM MgCl2) and grown with aeration for 1 h at 26 °C followed by 2 h at 37 °C. BMDMs were infected at a multiplicity of infection (MOI) of 20:1, unless otherwise noted. Cells were incubated at 37 °C and gentamicin (100 μg/mL) was added 1 h after infection. 100 μM zVAD-fmk (zVAD; SM Biochemicals), 60 μM necrostatin-1 (Nec-1; Calbiochem), 3 μM GSK2399872A (GSK’872; GlaxoSmithKline), 50μM TAPI-2 (Sigma), 80μM dynasore (Sigma) were added 1 h before infection where indicated.
+ Open protocol
+ Expand
6

ADAM17 Substrate Production Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols
For evaluating the production of ADAM17 substrates, the keratinocytes of scratch wound assay received 24h incubation in medium which did not contain any exogenous EGFR ligands, and were then collected following the process above mentioned 17 (link). Relevant DuoSet ELISA kits (Cloud-clone Corp, AREG SEA006Hu, HB-EGF SEB479Hu, TGF-α SEA123Hu, China) were used to analyze the collected medium specimens regarding the proteins. Supernatants were collected in triplicate for each cell line, and results from the vector and CD9-silenced keratinocytes treated with ADAM17 inhibitor TAPI-2 (Sigma, USA) at final concentration 40 μM.
+ Open protocol
+ Expand
7

ADAM17 Knockdown and Inhibition in Keratinocytes

Check if the same lab product or an alternative is used in the 5 most similar protocols
On-target siRNA specific to ADAM17 (GenePharma, China) was used to carry out siRNA knockdown on cells under culture. Briefly, penicillin- and streptomycin-free medium, which contained 0.1 μM ADAM17 or non-targeting pool (NTP) siRNA, were used to incubate the keratinocytes for 24 h. Western blot was employed to evaluate ADAM17 expression. Keratinocytes were treated with ADAM17 inhibitor TAPI-2(Sigma CAS 187034-31-7, USA) at final concentration 40 μM and recombinant human heparin-binding EGF (Abcam ab167830, UK) at final concentration 50 mg.
+ Open protocol
+ Expand
8

Lipid Signaling Molecules and Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
18:1. lysophosphatidylserine (LysoPS), 18:1 lysophosphatidylcholine (LysoPC), and 18:1 lysophosphatidylethanolamine (LysoPE) were purchased from Avanti Polar Lipids (Alabaster, AL, USA). Epidermal growth factor (EGF) and TGF-α neutralizing antibody were obtained from R&D Systems (Minneapolis, MN, USA). EGFR neutralizing antibody (clone LA1), Z-VAD-fmk, BAY11-7082, diphenyleneiodonium chloride (DPI), N-acetyl-L-cysteine (NAC), TAPI2, suramin, and A438079, Ac-YVAD-cmk were purchased from Sigma-Aldrich (St. Louis, MO, USA). U0126 and AG1478 were purchased from Calbiochem (La Jolla, CA, USA). SB203580 and SP600125 were obtained from Tocris Bioscience (Bristol, UK). PTX, a Gi/o protein inhibitor, was supplied by Invitrogen Life Technologies (Carlsbad, CA, USA). C29 was purchased from Biovision (Milpitas, CA, USA).
+ Open protocol
+ Expand
9

MCF-10A Cells Treated with TAPI-2

Check if the same lab product or an alternative is used in the 5 most similar protocols
MCF-10A cells were treated for 48 h with 20 µM TAPI-2 (TNF protease inhibitor 2) acetate salt (Sigma-Aldrich, Germany). The culture supernatant was tested for the presence of IL-6 and sIL-6RA by ELISA.
+ Open protocol
+ Expand
10

ADAM17 Regulation of EGFR Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols
ADAM17‐small interference RNA (target sequence of 5′‐CCAUGAACACGUGU‐3′) and a negative control (NC) siRNA (target sequence of 5′‐UUACACGUGUUCUUCAUGGT‐3′) were purchased from GenePharma (China). In brief, the cell monolayer was incubated in penicillin‐ and streptomycin‐free culture medium involved in 0.1 μM ADAM17‐siRNA or NC siRNA for 24 hours. Western blot and immunofluorescence were used for evaluating ADAM17 expression. Cell monolayer was treated with ADAM17 inhibitor TAPI‐2 (Sigma CAS 187034‐31‐7, USA) at a final concentration of 40 μM, EGFR inhibitor AG1478 (Calbiochem, La Jolla, CA) at a final concentration of 10 μM and recombinant human heparin‐binding EGF (R&D Systems, Wiesbaden‐Nordenstadt, Germany) at a final concentration of 100 ng/ml.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!